A Randomized, Double Blind, Multi Center, Parallel Study to Evaluate the Efficacy and Safety of Tacrolimus Lipid Tablets (Manufactured By Intas Pharmaceuticals Ltd) Compared to Prograf (Tacrolimus Immediate Release Capsules-Astellas Pharma Canada, Inc) in Adult Patients with Active Rheumatoid Arthritis Who Have Resistance OR Intolerance to DMARDs. - NA

Trial Profile

A Randomized, Double Blind, Multi Center, Parallel Study to Evaluate the Efficacy and Safety of Tacrolimus Lipid Tablets (Manufactured By Intas Pharmaceuticals Ltd) Compared to Prograf (Tacrolimus Immediate Release Capsules-Astellas Pharma Canada, Inc) in Adult Patients with Active Rheumatoid Arthritis Who Have Resistance OR Intolerance to DMARDs. - NA

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Sep 2016

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Intas Pharmaceuticals
  • Most Recent Events

    • 02 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top